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West Nile virus (WNV) causes epidemics of febrile ill-
ness, meningitis, encephalitis, and flaccid paralysis. Since
it was first detected in New York City in 1999, and through
2004, >16,000 WNV disease cases have been reported in
the United States. Over the past 5 years, research on WNV
disease has expanded rapidly. This review highlights new
information regarding the virology, clinical manifestations,
and pathology of WNV disease, which will provide a new
platform for further research into diagnosis, treatment, and
possible prevention of WNV through vaccination. 
T
he impressive spread of West Nile virus (WNV) in the
Western Hemisphere after its detection in 1999 during
an outbreak of encephalitis in New York City has caused
>16,000 human disease cases and >660 deaths in North
America. Research on the signs, symptoms, and pathogen-
esis of WNV disease has greatly intensified in the past 5
years. The number of recognized cases of flaccid paralysis
due to WNV infection has increased substantially, and
research into prognosis and possible therapy has expanded.
Genetic variation of the virus has been further character-
ized and continues to be explored. The pathology and
pathogenesis of WNV disease have been described more
completely than ever before. Several strategies are being
pursued to develop effective vaccines to prevent WNV dis-
ease. This article highlights new information about the
virology, clinical manifestations, laboratory diagnosis,
pathology, and prognosis of WNV illness in humans. The
expanded knowledge about WNV disease provides a new
platform for future development of diagnostic tests, thera-
py, and vaccine development. 
Characteristics of West Nile Virus
WNV is an arbovirus in the family Flaviridae. Its
spherical, enveloped capsid has a diameter of ≈50 nm and
contains single-stranded RNA that encodes the capsid (C),
envelope (E), and premembrane (prM) proteins, as well as
7 nonstructural proteins that likely contribute to viral repli-
cation. The virus has 2 genetic lineages: lineage 1 strains
are found in North America, Europe, Africa, Asia, and
Australia; lineage 2 strains have been isolated only in sub-
Saharan Africa and Madagascar. Lineage 1 strains have
been further divided into 4 clades: Kunjin, Indian, A, and
B (which includes an Indian isolate) (1). The isolates in
clade B, which includes strains from the United States, are
all virulent in mice; lineage 2 and other clades in lineage 1
comprise both virulent and attenuated strains (1).
Differences in pathogenicity may be related to nucleotides
that code for specific regions in the prM, E, or nonstructur-
al proteins of the virus (1,2). 
WNV strains from the United States are closely related
to strains from Israel, with 99.7% homology in nucleotide
sequences, indicating that the strains in the United States
almost certainly originated from the Middle East (3). The
strain isolated in New York in 1999 is more virulent in
American crows (Corvus brachyrynchos) than strains from
Kenya and Australia (Kunjin virus, a subtype of WNV),
and both the New York strain and the Kenyan strain exper-
imentally killed house sparrows whereas the Australian
strain did not (4). 
Two genetic variants of the North American WNV
strain were isolated in Texas in 2002; the major variant dif-
fered from the New York 1999 isolate by 0.18% of
nucleotides, and the minor variant by 0.35% (1). The 2
variants differed from each other by 0.5% of nucleotides,
and their neuroinvasiveness in mice was similar to that of
the New York 1999 isolate. In 2003, attenuated WNV
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the first evidence of phenotypic variation of WNV strains
in the Western Hemisphere (2,5). The reduced neuroinva-
siveness and smaller plaque size of the Texas strains may
be due to mutations in nonstructural proteins that result in
lower levels of viremia; the attenuated strain from Mexico
had a mutation in the E protein (2,5).
Pathogenesis 
WNV is thought to replicate at the site of inoculation
and then spread to lymph nodes and the bloodstream (6).
Viral penetration of the central nervous system appears to
follow stimulation of toll-like receptors and increased lev-
els of tumor necrosis factor-α, which increases permeabil-
ity of the blood-brain barrier (7). WNV directly infects
neurons, particularly in deep nuclei and gray matter of the
brain, brainstem, and spinal cord (8–10). Collateral
destruction of bystander nerve cells may contribute to
paralysis (11). Immune-mediated tissue damage may also
contribute to pathologic changes in some cases (12).
Genetic susceptibility for severe disease in mice has been
postulated to involve a deficiency in production of 2′–5′-
oligoadenylate synthetase, but this genetic susceptibility
has not been elucidated in humans (10). Although most
nonfatal WNV infections appear to be cleared by the host
immune response, the virus may persist in some vertebrate
hosts (10,13). 
Clinical Manifestations
The clinical spectrum of symptomatic WNV infection
in humans has been further defined during the North
American epidemics. About 80% of human infections are
apparently asymptomatic (14). Of those persons in whom
symptoms develop, most have self-limited West Nile fever
(WNF), characterized by the acute onset of fever,
headache, fatigue, malaise, muscle pain, and weakness;
gastrointestinal symptoms and a transient macular rash on
the trunk and extremities are sometimes reported (15,16).
A recent follow-up study of WNF patients who sought
medical attention found that difficulty concentrating and
neck pain or stiffness were also prominent symptoms, and
that fatigue and muscle weakness frequently lasted for ≈1
month after onset (16). Of the 98 patients interviewed,
31% were hospitalized, 79% missed school or work
because of their illness, and the median time before
patients felt fully recovered was 60 days. These patients
probably represent the most severe WNF, but even without
neurologic manifestations, WNV infection clearly can
cause a notable public health problem, Additional nonneu-
rologic clinical manifestations that may rarely occur dur-
ing WNV infection include hepatitis, pancreatitis,
myocarditis, rhabdomyolysis, orchitis, and ocular manifes-
tations (17–24). Chorioretinitis may be more common than
previously thought; a study in Tunisia found that 69% of
29 patients hospitalized with WNV disease had choriore-
tinitis (24). Cardiac dysrhythmias have been observed in
some North American patients (Centers for Disease
Control and Prevention [CDC], unpub. data) (22). 
Neuroinvasive disease develops in <1% of WNV-
infected persons, for example, in such forms as meningitis,
encephalitis, or paralysis (the proportion of reported cases
that are neuroinvasive disease is higher because neuroin-
vasive disease is more likely to be reported than WNF or
asymptomatic infections) (14). The risk for encephalitis
increases with age and is higher among organ transplant
recipients (25,26). Whether other immunocompromised
patients are at higher risk remains unclear, but severe
WNV disease has been described in persons with malig-
nancies (9). Whether diabetes, hypertension, and cere-
brovascular disease are risk factors also remains uncertain
(27). The clinical severity of WNV encephalitis ranges
from mild disorientation to coma and death (28,29). Many
patients with WNV encephalitis have movement disorders,
including severe tremors and parkinsonism (28,29). 
In ≈13% of patients with neuroinvasive WNV disease,
WNV infection of spinal motor neurons (anterior horn
cells) causes acute, asymmetric flaccid paralysis similar to
that seen with poliomyelitis (CDC, unpub. data)
(18,30,31). Infection of the brainstem and high cervical
spinal cord may cause diaphragmatic and intercostal mus-
cle paralysis with resulting respiratory failure and some-
times death. A separate syndrome consistent with acute
inflammatory demyelinating polyradiculoneuropathy
(Guillain-Barré syndrome) has been infrequently reported
(32).
Pathologic Changes
Histologic findings of WNV encephalitis include
perivascular inflammation, microglial nodules, variable
necrosis, and loss of neurons (Figure panels A, B) (8,9).
The deep gray nuclei, brainstem, and spinal cord appear to
be most affected (8,9). Patients with flaccid paralysis have
perivascular lymphocytic infiltration in the spinal cord,
microglial nodules, and loss of anterior horn cells (9).
Spinal cord inflammation was seen in 17 of 23 people who
died with WNV neuroinvasive disease; inflammation was
more prominent in the anterior horns than in the posterior
horns of 9 patients (9). Endoneural mononuclear inflam-
mation of cranial nerve roots and spinal nerves can be
found in a small percentage of persons. Foci of demyelina-
tion, gliosis, and occasional perivascular infiltrates may be
found in persons with prolonged clinical courses.
Before 2001, attempts to isolate WNV from post-
mortem tissues in the United States had been unsuccessful.
Recently, the virus has been isolated postmortem from 2
immunosuppressed patients with apparently high viral
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sensitive than viral culture, showing WNV antigens in
≈50% of fatal WNV neuroinvasive disease cases; IHC
staining is particularly useful in patients who died during
the first week of illness when viral antigen concentrations
in central nervous system (CNS) tissues are high (9). Viral
antigens are usually found within neurons and neuronal
processes, predominantly in the brain stem and anterior
horns (Figure, panel C). In general, antigens are focal and
sparse, except in immunosuppressed patients in whom
they can be seen extensively throughout the CNS (9).
Visualization of WNV particles by electron microscopy is
rare. When found, they are seen within endoplasmic retic-
ulum of neurons (Figure, panel D). 
Diagnostic Tests
Routine clinical laboratory studies do not distinguish
WNV infection from many other viral infections. Patients
with neuroinvasive disease generally have lymphocytic
pleocytosis in the cerebrospinal fluid (CSF), but neu-
trophils may predominate early in the course of illness
(28,31). Results of brain magnetic resonance imaging are
frequently normal, but signal abnormalities may be seen in
the basal ganglia, thalamus, and brain stem of patients with
encephalitis, and in the anterior spinal cord in patients with
poliomyelitislike syndrome (18,29,31). Clinical features
and electrodiagnostic tests can help differentiate
poliomyelitislike syndrome from Guillain-Barré syndrome
by localizing damage primarily to motor axons, anterior
horn cells, or both, with relative sparing of sensory nerves
in the former, as opposed to localizing the damage to
peripheral myelin or muscle in the latter (18,31,32,34).
Detection of WNV-specific immunoglobulin (Ig) M in
serum or CSF provides strong evidence of recent WNV
infection. In some patients, IgM antibody against WNV is
usually detectable by 8 days after illness onset; however, in
patients with WNV neuroinvasive disease, specific IgM is
almost always detectable in serum and CSF by the time
CNS symptoms begin (35). Among asymptomatic WNV-
viremic blood donors who were seronegative at the time of
donation, IgM appeared ≈9 days postdonation, and IgG
appeared ≈4 days later (M. Busch, pers. comm.). IgM is
detectable in serum of ≈36% of patients who have survived
WNV encephalitis at 12 months postonset and ≈20% at 16
months postonset; IgM is also detectable in CSF of other
patients up to 199 days postonset (36,37). Consequently,
detectable IgM may occasionally reflect past rather than
recent infection. 
Recently developed microsphere immunoassays for
WNV antibody appear to be more accurate and efficient
than current enzyme immunoassays (EIAs) (J. Johnson,
pers. comm.) (38). As with standard EIA, related flaviviral
infection may elicit cross-reactive test results. A micros-
phere assay with nonstructural viral antigens appears to
discriminate between primary flaviviral infections that
elicit cross-reactive antibody to the E glycoprotein (38).  
A> 4-fold change in virus-specific neutralizing anti-
body titer (detected by plaque-reduction neutralization test
[PRNT]) between 2 serum specimens collected 2–3 weeks
apart usually confirms acute WNV infection. Samples with
WNV-specific antibody will usually have neutralizing
antibody titers to WNV that are >4-fold higher than titers
to other epidemiologically relevant flaviviruses included
in the assay. However, PRNT may not discriminate
between WNV infection and other flaviviral infections in
patients with previous flavivirus exposure, because the
neutralizing antibody in such cases may broadly cross-
react to several related flaviviruses.  
WNV infection can also be diagnosed by detecting
virus in CSF, serum, or tissues by isolation or nucleic acid
amplification tests (NATs). WNV is best isolated in cell
culture or suckling mice and identified by indirect
immunofluorescence assay with specific monoclonal anti-
bodies or by reverse transcriptase–polymerase chain reac-
tion (RT-PCR). However, WNV is rarely isolated from the
blood of patients with neuroinvasive WNV disease
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Figure. Histopathologic features of West Nile virus (WNV) in
human tissues. Panels Aand B show inflammation, microglial nod-
ules, and variable necrosis that occur during WNV encephalitis;
panel C shows WNV antigen (red) in neurons and neuronal
processes using an immunohistochemical stain; panel D is an
electron micrograph of WNV in the endoplasmic reticulum of a
nerve cell (arrow). Bar = 100nm.because viremia levels are typically low or absent by the
time neurologic symptoms develop. Real-time RT-PCR
and nucleic acid sequence-based amplification are the
most sensitive NATs, able to detect >50 viral RNA copies
per mL (≈0.1 PFU/mL), which is ≈1,000-fold more sensi-
tive than culture (39). WNV can be detected in serum by
NAT if the specimen is obtained early in infection and is
readily detected by NAT, isolation, or IHC staining in brain
tissue from persons with fatal cases. The sensitivity of RT-
PCR among 28 patients with serologically confirmed neu-
roinvasive WNV disease was 57% in CSF and 14% in
serum (40).
The diagnosis of WNV encephalitis can be supported
histopathologically, and there is no pathognomonic lesion.
Differential diagnoses include arboviral and other viral
encephalitides, rickettsial infections, and various noninfec-
tious diseases. When serum samples and frozen tissues are
not available, IHC testing of formalin-fixed tissues with
specific monoclonal and polyclonal antibodies is particu-
larly useful.
Prognosis
The clinical course of WNF ranges from a mild febrile
illness of several days’ duration to debilitating fatigue,
aching, and weakness that may last for weeks or months
(16,29,41). Although cases of meningitis without alteration
of the patient’s mental status or other focal neurologic fea-
tures have a favorable prognosis, persistent headaches and
fatigue may be reported (29). Patients with WNV
encephalitis or focal neurologic manifestations often have
persistent neurologic deficits for months or years (28,29).
Of 35 patients hospitalized with WNV disease in New
York, only 13 (37%) reported full recovery in physical,
cognitive, and functional abilities 12 months after illness
onset (41). Many patients with WNV-associated
poliomyelitislike syndrome do not recover, but some
improvement in limb strength may occur over time
(42,43). The overall case-fatality rate for neuroinvasive
WNV disease is ≈9% (26). 
Clinical Management
Management of severe WNV illness remains support-
ive. Patients with severe meningeal symptoms often
require pain control for headaches and antiemetic therapy
and rehydration for associated nausea and vomiting.
Patients with severe encephalitis should be observed for
development of elevated intracranial pressure and seizures,
and patients with encephalitis or paralysis must be moni-
tored for inability to protect the airway. Acute neuromus-
cular respiratory failure may develop rapidly, particularly
in patients with prominent bulbar signs; prolonged ventila-
tory support may be required (22,30,34). 
Ribavirin, interferon-α, WNV-specific immunoglobu-
lin, and antisense gene–targeted compounds have all been
considered as specific treatments for WNV disease, but no
rigorously conducted clinical trials have been completed.
Nonspecific immunoglobulin and plasmapheresis should
be considered for patients with Guillain-Barré syndrome
but are not indicated for patients with paralysis due to
damage of anterior horn cells (30). 
Vaccine Development 
Two vaccines are available for vaccinating equines: an
inactivated WNV vaccine and a recombinant vaccine that
uses canarypox virus to express WNVantigens (44,45). An
inactivated vaccine is also being studied for use in humans
(46). Achimeric live virus vaccine incorporating the genet-
ic sequences for E and prM antigens into a 17-D yellow
fever virus backbone has been shown to be efficacious in
hamsters and is undergoing initial clinical trials in humans
(46). Another chimeric vaccine incorporating WNV genet-
ic sequences into a backbone of attenuated serotype-4
dengue virus–induced protective immunity in monkeys
(44). ADNAvaccine that elicits expression of WNV E and
prM antigens has been used in mice, horses, and birds (44).
Vaccination of crows with Kunjin virus, a subtype of
WNV, protected against WNV, and a DNA vector, which
elicited expression of attenuated Kunjin virus, provided
protective immunity against WNV in mice (46). 
Future Directions
Since the 1990s, WNV has gained notoriety as a cause
of severe neuroinvasive disease in humans. As WNV iso-
lates and genetic sequences accumulate over an increasing
geographic and clinical range, the virus shows signs of
genetic modifications that likely interact with host factors
in causing different patterns of neuroinvasiveness and neu-
rovirulence. Several areas warrant research focus over the
next few years. More efficient diagnostic assays will help
with both clinical diagnosis and disease surveillance.
Improved knowledge about the pathogenesis and natural
history of WNV disease is crucial to developing effective
treatment, and promising therapies need to be carefully
evaluated in controlled clinical trials. Given the focal dis-
tribution of WNV outbreaks, and the uncertain distribution
of future cases of WNV disease, prospective clinical stud-
ies need to be designed with the flexibility to gather infor-
mation from widely dispersed and changing locations. The
development of a safe and effective vaccine for humans is
a clear priority for prevention, and the public health strate-
gies and recommendations for vaccination deserve careful
thought. Given the relatively low incidence of WNV neu-
roinvasive disease and the focal occurrence of WNV epi-
demics thus far, vaccination will likely require targeting to
higher risk groups to approach the cost-effectiveness of
many recommended public health prevention strategies.
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